6/C:4/C PMS186 PMS186 2ND MASIMO CORPORATION
MASIMO CORPORATION :: 2007 ANNUAL REPORTMasimo Corporation 40 Parker, Irvine, CA 92618 Tel 800-257-3810 Fax 949-297-7599 www.masimo.com7675-5040B-0408I AM MASIMO 2008 Masimo Corporation. All Rights Reserved.
I AM MASIMO: A diversity of talents, a unity of purpose.Each morning, a global team of more than 1,500 Masimo purists starts the day with a single focus. Whether it’s a researchengineer working to solve the next “unsolvable” problem, a clinical specialist helping a customer understand how our technologycan enhance patient safety, or a member of our logistics team making sure that a critical delivery gets out on time, their motivationis the same—to do what is best for patient care. At Masimo, we know that what we do matters. It matters to the clinicians aroundthe world who rely on our technologies to help them make accurate and timely diagnoses and treatment decisions. And it mattersto the patients for whom they are caring—whose lives are touched and enhanced by our single‑minded focus.Masimo Team (from left): Meghan Corradino, Human Resources; Anna Do, Finance; Juan Ayala, International Sales; Amir Moradi,Product Management; Man Minh Pham, Manufacturing; Jamison Gorin, Information Technologies; Dana Banks, Public Relations23
A letter from the Chairman.A Year of Important MilestonesSince this is our first Annual Report as a public company, we thought it would be appropriate to introduce you to some of thepeople who have helped make Masimo what it is today, as well as explain some of the underlying philosophies that guide us.2007 was a year of important milestones for Masimo. It began with the prestigious Excellence in Technology Innovationaward from the Society of Technology in Anesthesia (STA) for demonstrating the feasibility of noninvasive total hemoglobin(SpHb) monitoring. We launched PVI, which we believe is the first noninvasive way to measure patient volume and fluidresponsiveness in mechanically ventilated patients. And we expanded our Rainbow SET monitoring platform with the launchof our Radical-7 bedside monitor and family of Rainbow sensors. Numerous EMS and fire associations recommended theuse of Pulse CO-Oximetry to screen for carbon monoxide poisoning in firefighters, emergency personnel, and patients. Andlast but not least, we closed the year by shipping our 500,000th pulse oximeter and Pulse CO-Oximeter.These milestones, built on a solid foundation, fueled our strong financial performance in 2007—helping us achieve recordrevenues as we helped clinicians around the world provide better care for their patients. We delivered double-digit growth inboth product revenues, which increased 29 percent to a record 199.7 million, and product shipments, which grew by 20percent as we shipped a record 116,300 new Masimo SET and Masimo Rainbow SET oximeters worldwide.I am particularly proud that our progress was achieved by adhering to our guiding principles and staying focused onour long-standing mission of “improving patient outcomes and reducing cost of care by taking noninvasive monitoring tonew sites and applications.” By remaining dedicated to innovation and patient care, we have continually overcome thetechnological challenges of noninvasive patient monitoring. We have developed important new noninvasive measurementsand dramatically improved existing ones by making them more accurate, reliable, and clinically relevant than anyone everimagined possible.“We established Masimo with a strongset of guiding principles and a boldmission. Today, it is the purity of ourmission and guiding principles thatunderpin a Masimo brandbuilt on truth.”Our innovations have not only helped healthcare professionals save the lives of patients—and the eyesight of prematureinfants—but have also opened up new markets for us. According to industry analysts, our new technologies have creatednew market opportunities that expand our market potential from 1 billion to nearly 3 billion. With a continuing commitmentto innovation, accomplishment, and truth, we hope to continue to enhance patient care and expand the worldwidecommunity’s access to our technologies. In so doing, we will continue to build our total market opportunity and increasevalue for our shareholders.A Brand Built on TruthNineteen years ago, we established Masimo with a strong set of guiding principles and a bold mission that underpins aMasimo brand built on truth: truth in the pursuit of new, clinically-needed technologies that place patient safety and careabove all else; truth in the ability to accurately deliver trustworthy physiological information, even under the most difficultpatient conditions; truth in the independent and objective scientific research that underscores the ethics of the medicalcommunity; truth in our enduring commitment to providing clinicians with the tools they need to rapidly diagnose, treat,and deliver the most appropriate care with confidence; and truth in our unwavering commitment to do what is bestfor patient care.Joe E. KianiChairman & CEOMasimo Corporation45
In every way, in all that we do, Masimo stands for and is guided by truth. We have been since day one, customer one,Benzocaine administered during surgery to otherwise healthy adults. We were encouraged to see clinicians use PVIand shipment one—and will continue to strive to deliver truth through the Masimo brand.to determine patients’ fluid responsiveness, which helped them to more rapidly diagnose and treat patients who weredehydrated, overhydrated, or developing heart complications. And we saw a preview of the future benefits our technologiesA Company of “Purists”will bring when an engineering prototype of our noninvasive hemoglobin monitor helped save a doctor’s life (please seeWe define purists as people who do what they do because of the passion they have for their chosen field, not merely forpage 22 for the details).financial gain. Masimo is full of purists who love what they do, are passionate about their work, and are committed to goingabove and beyond what is expected to deliver solutions to unsolvable problems.Extending the Vision, Fulfilling the PromiseWhen solving the unsolvable problem of inaccurate arterial oxygen saturation and pulse rate measurements during motionand low perfusion required going to great lengths to achieve the “impossible,” we did it. When others couldn’t, wouldn’t, orsimply didn’t go far enough to innovate the solution, we did it. When bringing noninvasive monitoring technologies to newsites and new applications required starting a “second revolution” in patient monitoring, we did it. When doing what was bestfor patient safety and healthcare meant making technology upgrades available through simple software upgrades—again,we did it.Looking ahead, we anticipate that our latest revolutionary measurements—including our most recent introduction ofnoninvasive and continuous hemoglobin monitoring—will continue to make significant clinical contributions to patient care.Our new measurements allow us to extend the vision and promise of Masimo technologies beyond the hospital walls tothe scenes of emergencies, outpatient surgery centers, alternate care sites, and physician offices worldwide. And, as morehealthcare professionals gain access to our products, we look forward to saving and improving more lives and growing ourbusiness worldwide.None of this would have been possible without a dedicated team of purists—a team with a shared passion, vision, andsingle-minded focus to do what is best for patient care. This team is not confined within the walls of Masimo, but iscomprised of an extended group of purists, including passionate clinical researchers, clinicians, biomedical engineers,materials managers, OEM partners, and other stakeholders who love what they do and strive to make a difference. As weOur guiding principles, clinical contributions, and business model have allowed us to build a solid business. At the heart ofthis business is a great innovation engine with bright and talented engineers eager to solve a new set of clinical problemsand a team of purists ready to do what is right for patient care.continue to grow and expand, our greatest focus will be to continue to retain and attract Masimo purists.What a Difference Masimo Products Have MadeEach day, all over the world, our noninvasive blood constituent and hemodynamic monitoring technologies are helpingclinicians save, extend, or improve the lives of people of all ages, in all walks of life. This year, we witnessed countless EMSand fire departments using our portable, hand-held Pulse CO-Oximeters to save the lives of victims of carbon monoxidepoisoning.Joe E. Kiani470,000500,000 224.3377,000400,000We watched as neonatal clinicians used our pulse oximeters to monitor their patients not only to protect the brains, butsave the eyesight of extremely low birth‑weight infants by significantly reducing the risk of retinopathy of prematurity (ROP).200292,000300,000 199.7 155.1150213,000200,000 107.9100150,000In addition, clinicians conducting newborn screenings used our “gold standard” pulse oximeter’s measurement of arterialoxygen saturation and perfusion index to improve their detection rate for congenital heart defects (CHD). 256.3250 69.4104,000100,00038,0005062,000 14.4It was gratifying to see our noninvasive Rainbow SET platform warning clinicians of life-threatening levels ofdyshemoglobins—like methemoglobinemia induced by neonatal inhaled nitric oxide therapy or by drugs like0 20.9 38.3 46.7020002001200220032004200520062007Masimo SET Installed Base (estimated units)** Excludes Handheld Devices20002001200220032004200520062007Revenues (millions) Product Revenues Royalty RevenuesThe Masimo Product Offering:6Circuit BoardsMonitorsMonitoring SystemsSensorsThe leading measure-through-motionand-low-perfusion pulse oximetry solution,available in more than 100 OEM monitorsfrom more than 40 leading brands.A complete line of bedside and handhelddevices delivering Masimo SET and MasimoRainbow SET to clinicians in acute care,alternate care, and EMS/fire settings.Masimo recently introduced PatientSafetyNet, a wireless patient monitoring andclinician notification system designed to keeppatients safe on general-care floors.Available for either single-patient or multipatient use, we offer more than 100 differentsensor and cable combinations for virtuallyany clinical need.7
I AMINNOVATIONWhen Walt Weber joined Masimo as one of our first engineers more than 16 years ago, he was drawn bythe opportunity to make a difference in the lives of people. Coming from the defense industry, Walt sought acareer that would allow him to develop innovations that positively impacted society, yet still challenged him topush the boundaries of what was possible. Driven by a desire to look beyond the obvious, Walt’s commitmentto exploration and excellence helped bring some of our earliest technologies to market. And his continuingfocus on “solving the unsolvable” helps him lead and motivate the team to break new barriers today.A single-minded dedicationto discovery.Masimo engineers and scientists are a rare breed—a group of more than 100 purists who share a vision and apassion to make a difference for patient care. Driven by fascination and accomplishment, they are the reason we haveovercome challenges in noninvasive patient monitoring that others believed were impossible.That’s what we did in 1996 with Masimo SET, the first pulse oximetry technology that continued to measure when therewas patient motion and low perfusion—something other companies had given up trying to do. We followed up thataccomplishment in 2005 with the “second revolution,” Masimo Rainbow SET, the first noninvasive technology platformthat—with a single noninvasive sensor—can continuously measure many blood constituents that previously requiredinvasive blood sampling and laboratory analysis.But we’re not done yet. Innovation has been and will continue to be our passion. Today, Masimo scientists are hard atwork developing a whole new generation of breakthrough technologies, building on a solid foundation and continuallylooking beyond what others believe is possible.Walt Weber, Vice President, Algorithm DevelopmentAfter more than 16 years at Masimo, Walt has helped bring some of our most innovative technologiesto market—and his focus on solving the “unsolvable” is helping shape the technologies of tomorrow.89
commitment to continued growth More than 100 engineers in R&D Solving “unsolvable” clinically relevant problemsSET1989Masimo Corporationis foundedby Joe Kiani1995 2000Measure-through-motionand-low-perfusionpulse oximetry3-in-1 Pulse Oximeter— portable unit withdisplayFirst everFirst ever200520062007SpCOSpMetPVI First ever First everFirst everA single-minded dedicationto discovery.Masimo engineers and scientists are a rare breed—a group of more than 100 purists who share a vision and apassion to make a difference for patient care. Driven by fascination and accomplishment, they are the reason we haveovercome challenges in noninvasive patient monitoring that others believed were impossible.That’s what we did in 1996 with Masimo SET, the first pulse oximetry technology that continued to measure when therewas patient motion and low perfusion—something other companies had given up trying to do. We followed up thataccomplishment in 2005 with the “second revolution,” Masimo Rainbow SET, the first noninvasive technology platformthat—with a single noninvasive sensor—can continuously measure many blood constituents that previously requiredinvasive blood sampling and laboratory analysis.But we’re not done yet. Innovation has been and will continue to be our passion. Today, Masimo scientists are hard atwork developing a whole new generation of breakthrough technologies, building on a solid foundation and continuallylooking beyond what others believe is possible.Walt Weber, Vice President, Algorithm DevelopmentAfter more than 16 years at Masimo, Walt has helped bring some of our most innovative technologiesto market—and his focus on solving the “unsolvable” is helping shape the technologies of tomorrow.89
Masimo SET. Solving the “unsolvable.”Masimo’s Patent ProwessThe success of Masimo in the clinical environment isIn 1995 when we debuted Masimo SET, the world’s first and only pulse oximetry technology able to provide accuratemeasurements during patient motion and low perfusion, we were rewarded for our efforts with the prestigiousExcellence in Technology Innovation award from the Society for Technology in Anesthesia (STA). But while the STA andother leaders in the clinical community were convinced we had solved the “unsolvable” problem in pulse oximetry, asa new company with limited credibility, we needed independent clinical validation to overcome the noise created bycompetitors seeking to create uncertainty and cast doubt on our accomplishments.bolstered by our unwavering commitment to extend, protect,and defend what has become the industry’s highest-impactintellectual property estate. With 266 patents issued andanother 178 pending worldwide as of December 29, 2007,the strength of our underlying technologies has beenrecognized by and reported in leading business publications,including The Wall Street Journal, which in 2007 reportedOne of the first researchers to investigate our claims was Dr. Steven J. Barker, professor and head of the Departmentof Anesthesiology at the University of Arizona College of Medicine. In 1997, Dr. Barker and fellow researcher Dr. NitinK. Shah from the University of California, Irvine, published a breakthrough study concluding that Masimo SET provided“a significant advance in low signal-to-noise performance” resulting in “significant improvement in pulse oximeterperformance” during patient motion and low perfusion.1 Since this study, more than 100 independent and objectivestudies have reinforced the clinical superiority of Masimo SET to all other commercially available pulse oximeters.Signal Extraction Technology: Making the impossible possible.Masimo SET transformed the clinical landscape, using breakthrough signal-processing technologies—including parallelengines and adaptive filters—to deliver accurate and reliable SpO2 and pulse-rate measurements when conventionalpulse-oximetry technologies didn’t.that we had the fifth-strongest patent portfolio in the entiremedical-device industry.Masimo Rainbow SET. Extending“Masimo’sindustry impact scorethe vision.is the highest among all medtechThe launch of Masimo Rainbow SET in 2005 changed expectationscompanies,not to mention one ofof what could be measured by a single noninvasive sensor—winningthethehighestall companiesApplication ofamongTechnology awardfrom the Society for Technologyin Anesthesia (STA) in the process. By noninvasively and continuouslytrackedby The Patent Boardmeasuring carboxyhemoglobin and methemoglobin in addition to oxygensaturation,rate, and perfusion index, Rainbow SET gives clinicians aacross17pulseindustries.”more complete picture of their patients’ true oxygenation status. This picturebecomes even clearer with the introduction of total hemoglobin and oxygenRIRcontent.Noninvasive Hemoglobin a “Significant Advancement in Patient Care”Digitized, Filtered & Normalized In January 2007, a team of researchers from Loma Linda University’sR/IRDST FST SST MST ConventionalPulse OximetryAdaptive FilterCONFIDENCE MEASUREMENT CONFIDENCE MEASUREMENTAdaptive FilterDepartment of Anesthesiology won the prestigious Excellence in TechnologyInnovation award from the STA for their independent study demonstratingthat a preliminary Masimo engineering prototype could accurately measuretotal hemoglobin continuously and noninvasively. The team, led by Dr. MartinConfidence Based ArbitratorAllard, professor and director of research, and Dr. Mark Macknet, assistant professor and assistant director of clinical research, concluded that “rapidPost Processor clinical scenarios. This technology should allow for significant advances inDST Masimo SET 97%050%measurement of hemoglobin would be an extremely useful tool in many66%97%patient care.”1, 2100%SpO2%1 M acknet MR, Norton S, Kimball-Jones P, Applegate II R, Martin R, Allard M. Continuous Non-InvasiveMeasurement of Hemoglobin via Pulse CO-oximetry. Loma Linda (CA): Loma Linda University, Department ofAnesthesiology.2 M acknet MR, Norton S, Kimball-Jones P, Applegate II R, Martin R, Allard M. Continuous Non-InvasiveMeasurement of Hemoglobin via Pulse CO-oximetry During Liver Transplantation, a Case Report. Loma Linda(CA): Loma Linda University, Department of Anesthesiology.Steven J. Barker, MD, PhDDr. Barker was one of the first clinical researchers to study the performanceof Masimo SET pulse oximetry and performed some of the first experiments that validated theaccuracy and reliability of Masimo Rainbow SET.1 Barker SJ, Shah NK. The effects of motion on the performance of pulse oximeters in volunteers. Anesthesiology 1997:86(1):101-10810Mark Macknet, MD, (left) and Martin Allard, MD, M.B.Ch.B, FRCA (right)A series of studies preformed by Drs. Macknet and Allard showed that the ability to continuously and noninva‑sively measure total hemoglobin levels with Masimo Rainbow SET has the potential to improve clinical careand patient safety, while reducing the cost of care.Source: 2007 Patent ScorecardRanking of Industry Innovation, The Patent Board11
Masimo SET. Solving the “unsolvable.”An Upgradable Platformfor Growth, An UnbeatableRecord of InnovationIn 1995 when we debuted Masimo SET, the world’s first and only pulse oximetry technology able to provide accuratemeasurements during patient motion and low perfusion, we were rewarded for our efforts with the prestigiousExcellence in Technology Innovation award from the Society for Technology in Anesthesia (STA). But while the STA andThe noninvasive blood-constituent-monitoring platformother leaders in the clinical community were convinced we had solved the “unsolvable” problem in pulse oximetry, asof Masimo Rainbow SET is an upgradable technologya new company with limited credibility, we needed independent clinical validation to overcome the noise created bythat allows clinicians to add new measurements andcompetitors seeking to create uncertainty and cast doubt on our accomplishments.parameters as they need them—all through a simplefield-installed software upgrade.One of the first researchers to investigate our claims was Dr. Steven J. Barker, professor and head of the Departmentof Anesthesiology at the University of Arizona College of Medicine. In 1997, Dr. Barker and fellow researcher Dr. NitinCustomers can start with a Masimo Radical-7 bedsideK. Shah from the University of California, Irvine, published a breakthrough study concluding that Masimo SET providedmonitor loaded with Masimo SET oxygen saturation“a significant advance in low signal-to-noise performance” resulting in “significant improvement in pulse oximeter(SpO2), pulse rate, and perfusion index, then purchaseperformance” during patient motion and low perfusion.1 Since this study, more than 100 independent and objectivesoftware upgrades for additional measurementsstudies have reinforced the clinical superiority of Masimo SET to all other commercially available pulse oximeters.whenever they need them. Current upgradablenoninvasive measurements include the following:Masimo Rainbow SET. Extendingthe vision.The launch of Masimo Rainbow SET in 2005 changed expectationsof what could be measured by a single noninvasive sensor—winningSignal Extraction Technology: Makingthe impossiblepossible.Methemoglobin Carboxyhemoglobin(SpCO ) andthe Application of Technology award from the Society for Technology(SpMet )—two critical dyshemoglobins proven toincrease morbidityand mortality in a broadrange ofMasimo SET transformed the clinical landscape, using breakthrough linicalsettingsengines and adaptive filters—to deliver accurate and reliable SpO and pulse-rate measurements when conventionalmeasuring carboxyhemoglobin and methemoglobin in addition to oxygen 2pulse-oximetry technologies didn’t.in Anesthesia (STA) in the process. By noninvasively and continuouslysaturation, pulse rate, and perfusion index, Rainbow SET gives clinicians amore complete picture of their patients’ true oxygenation status. This picture PVI —giving cliniciansthe ability to noninvasivelyRIRassess fluid responsiveness for the first time everbecomes even clearer with the introduction of total hemoglobin and oxygen Continuous and Noninvasive Hemoglobin (SpHb )and Oxygen Content (SpOC )—now available ontheDigitized,platformFiltered & NormalizedNoninvasive Hemoglobin a “Significant Advancementcontent. in Patient Care” In January 2007, a team of researchers from Loma Linda University’s R/IRDST FST SST MST ConventionalPulse OximetryAdaptive FilterCONFIDENCE MEASUREMENT CONFIDENCE MEASUREMENTAdaptive FilterDepartment of Anesthesiology won the prestigious Excellence in TechnologyInnovation award from the STA for their independent study demonstratingthat a preliminary Masimo engineering prototype could accurately measuretotal hemoglobin continuously and noninvasively. The team, led by Dr. MartinConfidence Based ArbitratorAllard, professor and director of research, and Dr. Mark Macknet, assistant professor and assistant director of clinical research, concluded that “rapidPost Processor clinical scenarios. This technology should allow for significant advances inDST Masimo SET 97%050%measurement of hemoglobin would be an extremely useful tool in many66%97%patient care.”1, 2100%SpO2%1 M acknet MR, Norton S, Kimball-Jones P, Applegate II R, Martin R, Allard M. Continuous Non-InvasiveMeasurement of Hemoglobin via Pulse CO-oximetry. Loma Linda (CA): Loma Linda University, Department ofAnesthesiology.2 M acknet MR, Norton S, Kimball-Jones P, Applegate II R, Martin R, Allard M. Continuous Non-InvasiveMeasurement of Hemoglobin via Pulse CO-oximetry During Liver Transplantation, a Case Report. Loma Linda(CA): Loma Linda University, Department of Anesthesiology.Both the Masimo Radical-7 (shown above) and the MasimoRad-87 bedside monitors can be enabled to display MasimoRainbow SET measurements through a simple field-installedsoftware upgrade.Steven J. Barker, MD, PhDDr. Barker was one of the first clinical researchers to study the performanceof Masimo SET pulse oximetry and performed some of the first experiments that validated theaccuracy and reliability of Masimo Rainbow SET.1 Barker SJ, Shah NK. The effects of motion on the performance of pulse oximeters in volunteers. Anesthesiology 1997:86(1):101-10810Mark Macknet, MD, (left) and Martin Allard, MD, M.B.Ch.B, FRCA (right)A series of studies preformed by Drs. Macknet and Allard showed that the ability to continuously and noninva‑sively measure total hemoglobin levels with Masimo Rainbow SET has the potential to improve clinical careand patient safety, while reducing the cost of care.11
I AMRESEARCHNeonatologist Dr. Augusto Sola has spent nearly 35 years improving the lives of some of the most fragileand important patients. His research has led to many clinical advances—including the use of Masimotechnology to change the way oxygen is administered to newborns, resulting in a dramatic decrease inneonatal eye damage. He is a passionate clinician and dedicated researcher, focused on improving patientcare and enhancing the quality of life for patients all over the world. As a world-renowned expert in the fieldof neonatology, Dr. Sola regularly collaborates with colleagues to advance the quality of care—sometimesone patient and sometimes thousands of patients at a time.A commitment to collaborativeexploration.Masimo is passionate about making innovative technologies that give clinicians the tools they need to do what is bestfor patient care. That’s why it is gratifying to see so many independent clinicians and clinical researchers take the timeto evaluate our products and technologies—and then to communicate the positive impacts on patient care and safetythat can be realized through their use.More than 100 independent and objective studies by researchers around the world have demonstrated the clinicaladvantages of our technologies. These studies have shown Masimo technologies can provide a dramatic reductionin eye damage in the NICU, allow congenital heart defects to be properly diagnosed, accurately measure cyanoticpatients at very low oxygen-saturation levels, lead to a reduction in medical errors, and much, much more.As we continue to raise the bar on what clinicians can expect from noninvasive patient monitoring technologies, welook forward to seeing how they put these technologies to work to improve patient care.Augusto Sola, MDDr. Sola is Director of Neonatal Research and Academic Affairs for Midatlantic Neonatology Associates (MANA) atAtlantic Health System, Morristown, New Jersey, and Professor of Neurosciences at UMDNJ. His groundbreakingresearch with Masimo technology at Cedars Sinai and Emory University has led to a significant reduction andprevention of neonatal blindness caused by retinopathy of prematurity (ROP) worldwide.1213
CLINICAL STUDIES DEMONSTRATE MASIMO SUPERIORITYMasimo technologies have been shown to be superior to other oximetry technologies in more than100 independent and objective studies.Summary of independant and objective studies involving Masimo pulse oximetryALLSTUDIES200COMPARISONS TO OTHER“NEXT GENERATION” TECHNOLOGIES182100150100801006050402570200 Favors Masimo Neutral Favors Another Product070 Favors Masimo Neutral Favors Another ProductA commitment to collaborativeexploration.Masimo is passionate about making innovative technologies that give clinicians the tools they need to do what is bestfor patient care. That’s why it is gratifying to see so many independent clinicians and clinical researchers take the timeto evaluate our products and technologies—and then to communicate the positive impacts on patient care and safetythat can be realized through their use.More than 100 independent and objective studies by researchers around the world have demonstrated the clinicaladvantages of our technologies. These studies have shown Masimo technologies can provide a dramatic reductionin eye damage in the NICU, allow congenital heart defects to be properly diagnosed, accurately measure cyanoticpatients at very low oxygen-saturation levels, lead to a reduction in medical errors, and much, much more.As we continue to raise the bar on what clinicians can expect from noninvasive patient monitoring technologies, welook forward to seeing how they put these technologies to work to improve patient care.Augusto Sola, MDDr. Sola is Director of Neonatal Research and Academic Affairs for Midatlantic Neonatology Associates (MANA) atAtlantic Health System, Morristown, New Jersey, and Professor of Neurosciences at UMDNJ. His groundbreakingresearch with Masimo technology at Cedars Sinai and Emory University has led to a significant reduction andprevention of neonatal blindness caused by retinopathy of prematurity (ROP) worldwide.1213
Maxime Cannesson, MDDr. Cannesson’s independent clinical studies presented at the American Society ofAnesthesiologists concluded, “PVI shows great promise for use in perioperative fluidoptimization, which will have both clinical and economical impact.”Clinically Proven PerformanceMasimo technologies have been shown to be superior in awide range of clinical settings and with a broad spectrumof patient populations.Using a new Masimo measurement fornoninvasive hemodynamic monitoring.Proven with Adults1Using Masimo Rainbow SET to screen for congenital heartdefects and other life-threatening conditions in infants.90%83%80%70%60%50%43%40%One of the newest measurements available with Masimo Rainbow30%SET is PVI, which captures vital hemodynamic changes that may10%28%It is especially rewar
Masimo Corporation 40 Parker, Irvine, CA 92618 Tel 800-257-3810 Fax 949-297-7599
02896_RAV4_Brochure SS 12.16.15 Saatchi & Saatchi 150 PMS186 PMS423 PMS425 GLOSS VARNISH RAV_MY16_0002_V001 RAV_MY16_0001_V001. Get ready to do more in the new 2016 Toyota RAV4. It's got the look you crave: a daring front end, restyled rear fascia, sleek exterior and stylish new wheels. Available integrated fog lights and new available LED .
AngularJS Tutorial, AngularJS Example pdf, AngularJS, AngularJS Example, angular ajax example, angular filter example, angular controller Created Date 11/29/2015 3:37:05 AM
be looking at him through this square, lighted window of glazed paper. As if to protect himself from her. As if to protect her. In his outstretched, protecting hand there’s the stub end of a cigarette. She retrieves the brown envelope when she’s alone, and slides the photo out from among the newspaper clippings. She lies it flat on the table and stares down into it, as if she’s peering .
North & West Sutherland LHP – Minutes 1/3/07 1 NORTH & WEST SUTHERLAND LOCAL HEALTH CARE PARTNERSHIP Minutes of the meeting held on Thursday 1st March 2007 at 12:00 noon in the Ben Loyal Hotel, Tongue PRESENT: Dr Andreas Herfurt Lead Clinician Dr Alan Belbin GP Durness Dr Cameron Stark Public Health Consultant Dr Moray Fraser CHP Medical Director Mrs Georgia Haire CHP Assistant General .
2016 h Autodesk d 3D designs onfidence us sign data. Sp maximize pr op, cloud, an Prev AutoCAD so with robust t ing TrustedD eed detailing oductivity. C d mobile solu iew ftware, one ools that can WG techno and docume onnect your w tions. AutoC Guide of the world’ produce alm logy, the ori ntation work workflow and AD delivers t s leading CAD ost any shap ginal and mo with tools b .
City of Alexandria, Virginia Department of Planning and Zoning 301 King Street, Room 2100 Alexandria, VA 22314 Alexandria’s Racial and Ethnic Groups and Foreign-Born Population A Brief Look at Diversity
Surat Akuan Pembida (SPP 10 Tahun 2010 bertarikh 16 Disember 2010) Lampiran H 28 12. Contoh Dokumen Perjanjian Lampiran I 29 - 36 13. Contoh Bon Pelaksanaan Lampiran J 37 - 39 JAUHILAH AMALAN RASUAH 1
sliding rear window crack in warranty claim verbiage. A leak in the primary urethane seal should be addressed by removing and resealing the window, using the standard service procedure from SI. R & R the roof rear spoiler and apply seam sealer to the rear sliding window top encapsulate, following the steps in the Service Procedure below.
